March 25, 2026

To whom it may concern:

Company Name:	TOHO HOLDINGS CO.,LTD.
Corporate Representative:	Hiromi Edahiro, Representative Director, President and CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Executive Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

Notice of Participation in Collabo CREATE CO., LTD.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro; hereinafter “TOHO HOLDINGS”) is pleased to announce that it has decided to participate in Collabo CREATE CO., LTD. (Headquarters: Chuo-ku, Tokyo; President: Hidetsugu Soejima; hereinafter, “Collabo CREATE”), a joint venture to be newly established by SUZUKEN CO., LTD. (Headquarters: Nagoya City, Aichi; President and CEO: Shigeru Asano) on April 1, 2026.

1. Background of Participation

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

The healthcare environment in Japan is facing structural challenges that are difficult for any single company to solve alone. These include the increasing complexity of demand driven by a declining birthrate, an aging population, and the expansion of home and community-based healthcare. Furthermore, the sector faces a shortage of human resources, regional maldistribution, and tightening logistics and delivery capacity—symbolized by the "2024 Problem in Logistics"—as well as the need to ensure stable supply during disasters and reduce environmental impact.

Collabo CREATE is an enterprise formed by companies united under the shared philosophy of "Contributing to society," with the goal of transcending traditional business boundaries to address these challenges. We believe that endorsing Collabo CREATE’s vision of a "Development of a Healthcare Logistics Business to Address Social Challenges" and building a sustainable medical supply chain together with partners from various industries will lead to the realization of our Group’s social mission.

2. The Role of Collabo CREATE

Collabo CREATE is a non-asset-based comprehensive solutions provider that brings together the assets, functions, and expertise of partner companies, with the participation of part-time directors and dedicated personnel from partner companies to design and propose optimal logistics solutions across a broad range of healthcare challenges.

In addition to ethical drugs, the scope covers healthcare products such as medical devices and supplies, diagnostic agents, nutrition-related products, and over-the-counter (OTC) products. Collabo CREATE will respond to the needs of manufacturers, medical institutions, and local communities from a neutral and independent position.

3. Overview of Collabo CREATE

Company name	Collabo CREATE CO., LTD.
Headquarters location	14F MSH Nihonbashi Hakozaki Building, 19-21 Nihonbashi Hakozakicho, Chuo-ku, Tokyo
Key executives	President, Hidetsugu Soejima and Director and Chairman, Shigeru Asano
Date of establishment	April 1, 2026 (scheduled)
Share capital	50 million yen (planned to increase to 100 million yen after the capital increase)
Business description	• Contract logistics services for pharmaceutical manufacturers • Comprehensive proposal and contract logistics services for healthcare products (including medical devices and supplies, OTC products, etc.)
Partner companies	Joint Venture Partnership: SUZUKEN CO., LTD, MITSUI-SOKO HOLDINGS Co., Ltd., Seino Holdings Co., Ltd., TOHO HOLDINGS CO.,LTD., OHKI HEALTHCARE HOLDINGS CO., LTD., YAGAMI CO., LTD. (Seiei Ailes Sante Holding Ltd.) and Miyano Medical Instruments Co., Ltd. Business Alliance: SoftBank Corp.